Clinical Trials
40 trialsAZUR-4
GlaxoSmithKline
Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
Peking University
EMPIRE
NSABP Foundation Inc
Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.
Shandong Cancer Hospital and Institute
NEOPRISM-CRC
University College, London
Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment
Emory University
PSI-Immune
University of Pittsburgh
SCOTI
Rutgers, The State University of New Jersey
FRUITFUL
SCRI Development Innovations, LLC
TRIUNITE-08
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
PILDI
Institute of Oncology Ljubljana
NICHE
The Netherlands Cancer Institute
Phase II Trial of Lung Chemoemobolization
City of Hope Medical Center
CHIMERA
Gruppo Oncologico del Nord-Ovest
Superhero
Universitaire Ziekenhuizen KU Leuven
PILDI
Institute of Oncology Ljubljana
Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery
Rutgers, The State University of New Jersey
MODIFI-L
Sixth Affiliated Hospital, Sun Yat-sen University
Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
City of Hope Medical Center
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
Emory University
NeoCHIC
Ruijin Hospital
Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
Ruijin Hospital
Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）
Hebei Medical University Fourth Hospital
SPARTA
Apollomics Inc.
Phase â…¡ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC
Fudan University
NAIO
University of Iowa
NICER
Baylor College of Medicine
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Vyriad, Inc.
ECLYPse
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC
Affiliated Hospital of Nantong University
CARE
Centre Hospitalier Universitaire de Besancon
MesaCAPP
Karolinska University Hospital
REVISE
West China Hospital
HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study
Al-Azhar University
The Effect of Probiotics ATG-F4 in Cancer Patients
Chungnam National University Hospital
Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
Sun Yat-sen University
CAPCET
West China Hospital
ICONIC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients
Odense University Hospital